A Phase 3 Trial of Telitacicept for Systemic Lupus Erythematosus

入射(几何) 医学 相(物质) 免疫学 抗体 红斑狼疮 内科学 临床试验 呼吸系统 结缔组织病 免疫病理学 抗体反应 免疫系统 自身抗体 自身免疫性疾病 呼吸道疾病 不利影响 呼吸道
作者
Ronald van Vollenhoven,Li Wang,Joan T. Merrill,Yi Liu,Chunde Bao,LI Fen,Jiankang Hu,Chenghui Huang,Jianhong Zhao,Cibo Huang,Hanyou Mo,Wei Wei,Fu’ai Lu,Jingyang Li,Dongbao Zhao,Wenxiang Wang,Lin Li,Qing Zuraw,Xiaofei Wang,Xuebin Wang
出处
期刊:The New England Journal of Medicine [Massachusetts Medical Society]
卷期号:393 (15): 1475-1485 被引量:67
标识
DOI:10.1056/nejmoa2414719
摘要

BACKGROUND: Telitacicept, a new dual inhibitor of the cytokines B-lymphocyte stimulator (BLyS) and APRIL (a proliferation-inducing ligand), showed efficacy in adults with active systemic lupus erythematosus (SLE) in a phase 2b trial when added to standard therapy. METHODS: We conducted a phase 3 trial in China in which participants with active SLE were randomly assigned (in a 1:1 ratio) to receive telitacicept (160 mg) or placebo subcutaneously once weekly for 52 weeks, in addition to standard therapy. The primary end point at week 52 was a response on the modified SLE Responder Index 4 (SRI-4), with a response on this composite measure defined as a reduction of at least 4 points in the Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) score (ranging from 0 to 105, with higher scores indicating greater disease activity), no new disease activity as measured on the British Isles Lupus Assessment Group index, and no worsening in the Physician's Global Assessment score. RESULTS: Of 433 adults screened, 335 underwent randomization (167 to the telitacicept group and 168 to the placebo group). At week 52, significantly more participants receiving telitacicept had a response on the modified SRI-4 than those receiving placebo (67.1% vs. 32.7%; adjusted difference, 34.5 percentage points; 95% confidence interval [CI], 24.3 to 44.7; P<0.001). A reduction of at least 4 points from baseline in the SELENA-SLEDAI score had occurred in 70.1% of the telitacicept group and in 40.5% of the placebo group (difference, 29.6 percentage points; 95% CI, 13.1 to 46.1). Adverse events that were considered by the investigator to be related to the trial regimen were more common with telitacicept than with placebo (74.9% vs. 50.0%). Such events that occurred more frequently in the telitacicept group than in the placebo group included upper respiratory tract infection (31.7% vs. 19.0%), a reduced serum IgG level (15.6% vs. 1.2%), a reduced serum IgM level (15.0% vs. 0.6%), and injection-site reactions (12.6% vs. 0.6%). CONCLUSIONS: In this 52-week trial involving participants with active SLE who were receiving background therapy, the incidence of a clinical response was higher with telitacicept than with placebo. However, the incidence of upper respiratory infections, reduced immunoglobulin levels, and injection-site reactions was also higher with telitacicept. (Funded by RemeGen; 18C010 ClinicalTrials.gov number, NCT04082416.).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
Doner完成签到,获得积分10
刚刚
1秒前
Kathy完成签到,获得积分10
1秒前
可爱的函函的应助被小艾同学采纳,获得10
1秒前
Cina完成签到,获得积分10
2秒前
缝纫工完成签到 ,获得积分10
3秒前
4秒前
4秒前
叁叁发布了新的文献求助10
4秒前
徐华佳发布了新的文献求助10
6秒前
徐睿完成签到,获得积分10
6秒前
6秒前
6秒前
molihuakai的应助被Kathy采纳,获得10
6秒前
酷波er的应助被暴龙战士采纳,获得10
7秒前
9秒前
文静念真发布了新的文献求助10
9秒前
两脚兽大人完成签到 ,获得积分10
9秒前
困困完成签到 ,获得积分10
10秒前
10秒前
11秒前
vamcello发布了新的文献求助10
11秒前
莓莓发布了新的文献求助10
12秒前
单薄雪巧完成签到 ,获得积分10
13秒前
13秒前
科研小白发布了新的文献求助10
13秒前
14秒前
14秒前
Tracy完成签到,获得积分10
15秒前
小艾同学发布了新的文献求助10
16秒前
吴剑锋完成签到 ,获得积分10
16秒前
水煮电吹风的应助被pp采纳,获得10
16秒前
16秒前
Luxury完成签到 ,获得积分10
16秒前
oo完成签到,获得积分10
18秒前
徐华佳完成签到,获得积分20
18秒前
哈哈哈完成签到,获得积分20
18秒前
糟糕的烤鸡完成签到,获得积分10
18秒前
cheng完成签到,获得积分20
20秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181498
求助须知:如何正确求助?哪些是违规求助? 9571421
关于积分的说明 21817968
捐赠科研通 7777967
什么是DOI,文献DOI怎么找? 3433508
关于科研通互助平台的介绍 2557696
邀请新用户注册赠送积分活动 2479552